IMVT News and Press, Immunovant Inc. From 07/19/23

2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...

2023-07-17 13:26:32 ET Shares of Immunovant ( NASDAQ: IMVT ) jumped 14% midday Monday amid the release of positive data for Argenx's ( ARGX ) drug Vyvgart Hytrulo, which is in the same drug class as Immunovant's drug candidate IMVT-1402. Argenx reported earlier Monday that a...

2023-07-17 08:53:44 ET Acumen Pharmaceuticals ( ABOS ) +103% to Hold Conference Call to Discuss Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease. BridgeBio Pharma ( BBIO ) +66% announces consistently positive resul...

2023-05-24 13:14:23 ET Summary Rating: Buy-rating maintained based on IMVT-1402's unique potential and impending Phase 1 catalyst in 2H 2023. Stock Upswing: Anticipate over 200% rise if Phase 1 MAD data showcases clean safety and broad autoimmune disease applicability. Argenx ...

Immunovant, Inc. (NASDAQ: IMVT) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.76% on the day to $23.93. Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401...

Investigational New Drug (IND) application and Clinical Trial Application (CTA) for IMVT-1402 cleared by the FDA and MEDSAFE, respectively Phase 1 clinical trial in healthy subjects initiated in New Zealand Phase 2 proof-of-concept clinical trial of batoclimab in Graves’ di...

2023-05-20 21:19:49 ET Summary argenx impresses with $218M Q1 Vyvgart revenue, exceeding consensus due to cyclical factors and early gMG therapeutic sequence adoption. The CIDP ADHERE trial carries inherent risks due to historically high placebo responses and mechanistic limitatio...

2023-04-25 11:06:14 ET For further details see: Immunovant a new buy at Citi on strong autoimmune pipeline

2023-03-30 10:51:52 ET Stifel has launched its coverage on clinical-stage biotech Immunovant ( NASDAQ: IMVT ) with a Buy rating and a $28 per share target, arguing that the company’s prospects extend beyond the autoimmune disorder myasthenia gravis. Immunovant ( IMV...

2023-03-06 17:07:59 ET Summary Immunovant's lead drug, batoclimab, is one of many FcRn antagonists, either approved or in development, for the treatment of autoimmune diseases, including myasthenia gravis (MG). In batoclimab clinical trials by Immunovant, safety concerns emerged w...